WO1997012614A1 - Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique - Google Patents
Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique Download PDFInfo
- Publication number
- WO1997012614A1 WO1997012614A1 PCT/EP1996/004327 EP9604327W WO9712614A1 WO 1997012614 A1 WO1997012614 A1 WO 1997012614A1 EP 9604327 W EP9604327 W EP 9604327W WO 9712614 A1 WO9712614 A1 WO 9712614A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- acid addition
- propyl
- treatment
- inhalation
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 11
- 150000003839 salts Chemical class 0.000 title claims description 11
- FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- KWFASKPXXSVNIQ-UHFFFAOYSA-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,4-diamine Chemical compound C1C(CCC)CC(N)C2=C1SC(N)=N2 KWFASKPXXSVNIQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002831 pharmacologic agent Substances 0.000 claims 2
- 208000027898 Parkinson disease 7 Diseases 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 9
- 229960003089 pramipexole Drugs 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000036765 blood level Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229940041682 inhalant solution Drugs 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
Definitions
- the present invention relates to the inhalation application of 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, in particular its (-) - enantiomer, and its pharmacologically acceptable acid addition salts.
- Parkinson's disease is usually treated by oral administration of drugs.
- the inhalative application proposed according to the invention brings with it significant advantages for Parkinson's patients which improve their living conditions. Parkinson's disease is associated with a state of sedation in many patients.
- the inhalation application of Pramipexole according to the invention leads to an exceptionally rapid rise in blood level values within a very short time (minutes), as a result of which the state of the inhibition of movement is quickly eliminated. When administered orally, it can take up to two hours until optimal blood levels are reached.
- 2-Amino-6n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole can be used in the form of its acid addition salts in the form of aqueous or ethanolic solutions for the preparation of an aerosol for use in accordance with the invention.
- the preferred acid addition salt is dihydrochloride.
- Devices for generating a metered dose aerosol are known from the prior art for the treatment of asthma diseases.
- a device as described in WO 91/14468 - Atomization Devices and Methods - is particularly preferred. is disclosed.
- the advantage of the device described there is that the propellant gases usually required for metered dose mhaiers (MDI's) for producing the aerosol can be dispensed with
- pramipexole can also be applied using a so-called powder inhaler, in which micronized particles in a range from 1 to 15, preferably 4 to 8, ⁇ m of the active ingredient are inhaled directly as a powder.
- Nembutal 30 mg / kg IV
- the active ingredient was administered by means of Respimat blood plasma level: inhalation 2 mg
- the buffer substances, the active substance and sodium pyrosulfite are successively dissolved in boiled water and cooled with CO 2 gassing. Make up to the given volume with boiled water and filter without pyrogen.
- the inhalation solution must be prepared and filled in darkened rooms.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne l'administration par inhalation de pramipexoles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU72856/96A AU7285696A (en) | 1995-10-04 | 1996-10-04 | Administration by inhalation of 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazol, in particular of its (-)enantiomer and its pharmacologically tolerable acid addition salts |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19536916.5 | 1995-10-04 | ||
| DE19536916A DE19536916A1 (de) | 1995-10-04 | 1995-10-04 | Inhalative Applikation von 2-Amino-6n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol, insbesondere seines (-)-Enantiomeren, sowie deren pharmakologisch verträgliche Säureadditionssalze |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997012614A1 true WO1997012614A1 (fr) | 1997-04-10 |
Family
ID=7773972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/004327 WO1997012614A1 (fr) | 1995-10-04 | 1996-10-04 | Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU7285696A (fr) |
| DE (1) | DE19536916A1 (fr) |
| WO (1) | WO1997012614A1 (fr) |
| ZA (1) | ZA968315B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2839431A1 (de) * | 1978-09-11 | 1980-03-20 | Dolorgiet Arzneimittelfabrik | Arzneimittel |
| EP0186087A1 (fr) * | 1984-12-22 | 1986-07-02 | Dr. Karl Thomae GmbH | Tétrahydro-benzothiazoles, leur procédé de préparation et leur utilisation comme intermédiaires ou médicaments |
-
1995
- 1995-10-04 DE DE19536916A patent/DE19536916A1/de not_active Withdrawn
-
1996
- 1996-10-03 ZA ZA968315A patent/ZA968315B/xx unknown
- 1996-10-04 WO PCT/EP1996/004327 patent/WO1997012614A1/fr active Application Filing
- 1996-10-04 AU AU72856/96A patent/AU7285696A/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2839431A1 (de) * | 1978-09-11 | 1980-03-20 | Dolorgiet Arzneimittelfabrik | Arzneimittel |
| EP0186087A1 (fr) * | 1984-12-22 | 1986-07-02 | Dr. Karl Thomae GmbH | Tétrahydro-benzothiazoles, leur procédé de préparation et leur utilisation comme intermédiaires ou médicaments |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA968315B (en) | 1997-04-04 |
| AU7285696A (en) | 1997-04-28 |
| DE19536916A1 (de) | 1997-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1178832B1 (fr) | Nouvelles compositions medicamenteuses a base de bromide de tiotropium et de salmeterol | |
| DE69721766T2 (de) | Neue arzneiformulierung | |
| DE69526425T2 (de) | Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen | |
| AT401615B (de) | Verwendung von speziellen 5ht3-antagonisten zur herstellung von arzneimitteln | |
| EP1121112B1 (fr) | Concentre stable de formoterol | |
| DE69511374T2 (de) | Neue und verbesserte aminoglykosidformulierung als aerosol | |
| DE69024672T2 (de) | Sprays zur Behandlung von Infektionen des Tractus Respiratorius | |
| DE60209511T2 (de) | Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten | |
| WO1997017971A1 (fr) | Utilisation d'epinastine pour traiter la douleur | |
| WO1994013287A1 (fr) | Utilisation de 2-amino-6-a-propyl-amino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) comme medicament a effet antidepresseur | |
| DE69427591T2 (de) | 7-(2-imidazolinylamino)quinolin-verbindungen als alpha-2 adrenorezeptor-agonisten | |
| EP2320878B1 (fr) | Monoterpène pour le traitement de maladies des voies respiratoires, en particulier de maladies bronchopulmonaires | |
| EP1526870A1 (fr) | Nouvelle combinaison de glucocorticoides et d'inhibiteurs de pde-4 pour traiter des maladies des voies respiratoires, des maladies allergiques, de l'asthme et des maladies pulmonaires chroniques obstructives | |
| EP1594500B1 (fr) | Traitement de maladies bacteriennes des organes respiratoires par application locale de fluoroquinolones | |
| DE10205274A1 (de) | Neue Arzneimittelkompositionen enthaltend neben Anticholinergika heterocyclische Verbindungen | |
| DE60315426T2 (de) | Pharmazeutische zusammensetzung enthaltend einen pde4 oder pde3/4 inhibitor und eine histaminrezeptorantagonisten | |
| DE69527713T2 (de) | Verbindunngen und zusammensetzungen zur verabreichung via inhalation und insufflierung | |
| DE3527587A1 (de) | Nasale zubereitungen | |
| DE3852717T2 (de) | Zusammensetzung für die Prophylaxe von Pneumocystis-carinii-Pneumonie. | |
| WO1997012614A1 (fr) | Administration par inhalation de 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazole, en particulier de son (-)enantiomere et des sels d'addition d'acide de celui-ci acceptables sur le plan pharmacologique | |
| AT396332B (de) | Pharmazeutische zusammensetzung | |
| DE602004003955T2 (de) | Nasale pharmazeutische zusammensetzung von piribedil | |
| EP0417637A2 (fr) | Utilisation des agonistes de l'autorécepteur de la dopamine dans le traitement de la toxicomanie | |
| DE60202299T2 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
| DE3302949C2 (fr) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR BY CA CN CZ EE HU IL JP KR KZ LT LV MX NO NZ PL RO RU SG SI SK TR UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |